Previous close | 0.0000 |
Open | 0.0000 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.0000 - 0.0000 |
52-week range | |
Volume | |
Avg. volume | N/A |
Market cap | 24.127M |
Beta (5Y monthly) | 1.33 |
PE ratio (TTM) | 42.70 |
EPS (TTM) | 0.0100 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
PARIS, January 27, 2023--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX) (Paris:ALONX), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced its financial agenda for 2023.
PARIS, January 25, 2023--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX) (Paris:ALONX), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative tumor specific drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today provides an update on the clinical development program of its first-in-class drug candidate AsiDNATM.
PARIS, January 18, 2023--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), hereafter "Onxeo" or the "Company", a clinical stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA damage response (DDR) mechanisms to fight rare or resistant cancers, today announces the availability of the preparatory documents for its Extraordinary General Meeting which will be held on Monday, February 6, 2023 at 2:00 p.m. at the Renaissance Paris Nobel Tour Eif